The Acne Medicine Market is Projected To Reach USD 10.8 billion By 2030, From USD 6.1 billion in 2022,Registering a CAGR Of 7.40% During The Forecast Period 2023-2030| Data By Contrive Datum Insights Pvt Ltd.
11 mai 2023 17h00 HE
|
Contrive Datum Insights Pvt Ltd
Farmington, May 11, 2023 (GLOBE NEWSWIRE) -- The Global Acne Medicine market size was valued at USD 6.1 billion in 2022 and is projected to reach USD 10.8 billion by 2030, growing at a CAGR of 7.40%...
InSourceRx Announces Partnership With MDsave
28 juil. 2021 11h57 HE
|
InSourceRx
Omaha, Neb., July 28, 2021 (GLOBE NEWSWIRE) -- InSourceRx, a Nebraska-based pharmacy discount card company, and MDsave, a healthcare e-commerce technology company, announced a partnership that...
Rising Protocol Design Complexity Is Driving Rapid Growth in Clinical Trial Data Volume, According to Tufts Center for the Study of Drug Development
12 janv. 2021 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Ever more complex clinical trial designs are collecting much higher volumes of data from a variety of sources, intensifying pressure on drug sponsors to...
Online Pharmacy Market revenue to cross USD 149 Bn by 2026: Global Market Insights, Inc.
10 déc. 2020 05h00 HE
|
Global Market Insights, Inc
Selbyville, Delaware, Dec. 10, 2020 (GLOBE NEWSWIRE) -- According to latest report “Online Pharmacy Market by Product Type (OTC Medicine, Prescription Medicine), Therapy Area (Weight Loss,...
Kenneth I Kaitin to Retire from the Tufts Center for the Study of Drug Development after Leading the Organization for 23 Years
08 déc. 2020 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, Dec. 08, 2020 (GLOBE NEWSWIRE) -- The Tufts Center for the Study of Drug Development (CSDD), the leading independent source of authoritative analyses on the nature and pace of pharmaceutical...
Transition to Decentralized Clinical Trials during the Coronavirus Pandemic Is far More Nuanced than Expected, According to Tufts Center for the Study of Drug Development
12 nov. 2020 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) -- The coronavirus pandemic has facilitated rapid adoption of decentralized clinical trial execution, with more than half of all global clinical trials now...
Faster New Drug Approval Times Are More Than Offset by Longer Clinical Times in U.S., According to Tufts Center for the Study of Drug Development
16 juil. 2020 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, July 16, 2020 (GLOBE NEWSWIRE) -- Although regulatory approval time for new drugs in the United States is shortening, the time needed, on average, to complete clinical development of those...
Tufts Center for the Study of Drug Development Establishes Demographic Benchmarks for Pivotal Clinical Trials, Showing Areas of Under-Representation
12 mai 2020 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, May 12, 2020 (GLOBE NEWSWIRE) -- Although up to 90% of pivotal clinical trials for drugs approved for sale in the United States provide data on study participants by sex, race, and age, less...
Drug Developers Are Responding to Evolving Data Demands with New Strategies and Tactics, According to Tufts Center for the Study of Drug Development
17 mars 2020 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, March 17, 2020 (GLOBE NEWSWIRE) -- Rapid growth in data volume and the diversity of data sources are leading drug developers to plan and adopt data management strategies and tactics to help...
Drug Developers Are Making Strides in Streamlining Patient Recruitment and Retention for Clinical Trials, According to Tufts Center for the Study of Drug Development
28 janv. 2020 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Efforts by drug developers during the last decade to improve recruitment and retention of patients for clinical trials appear to be paying off, as...